Related Experiment Videos
Antibody response of mice to chemically induced tumors
Abstract:
BALB/c mice immunized with syngeneic methylcholanthrene-induced fibrosarcomas did not have antibodies against the unique tumor-specific transplantation antigens, even though they were capable of rejecting a lethal dose of tumor cells. Endogenous murine leukemia virus antigens expressed by certain of the tumors did, however, elicit high titers of antibodies, accounting for serological crossreactions that occurred between those tumors.
Insights
Mice rejected fibrosarcomas without antibodies to unique tumor antigens. However, antibodies to murine leukemia virus antigens caused cross-reactions between tumors, highlighting immune complexities in cancer research.
Area of Science:
- Immunology
- Oncology
- Virology
Background:
- BALB/c mice immunized with syngeneic methylcholanthrene-induced fibrosarcomas exhibit tumor rejection capabilities.
- The presence of unique tumor-specific transplantation antigens (TSTA) is often associated with tumor rejection.
- Serological cross-reactions between tumors can complicate the identification of specific tumor antigens.
Purpose of the Study:
- To investigate the antibody response in mice immunized with syngeneic fibrosarcomas.
- To determine if antibodies against unique tumor-specific transplantation antigens are generated.
- To elucidate the role of endogenous murine leukemia virus (MuLV) antigens in serological cross-reactions.
Main Methods:
- Immunization of BALB/c mice with methylcholanthrene-induced fibrosarcomas.
- Assessment of antibody titers against tumor antigens.
- Evaluation of tumor rejection capabilities following immunization.
- Analysis of endogenous murine leukemia virus antigen expression in tumors.
Main Results:
- Mice immunized with fibrosarcomas rejected lethal tumor doses despite lacking antibodies to unique TSTA.
- High titers of antibodies were detected against endogenous murine leukemia virus antigens present in certain tumors.
- These MuLV-specific antibodies were responsible for observed serological cross-reactions between tumors.
Conclusions:
- Tumor rejection in this model is not solely dependent on antibodies against unique TSTA.
- Endogenous MuLV antigens can act as immunodominant targets, leading to cross-reactivity.
- Understanding these immune responses is crucial for developing effective cancer immunotherapies.